8-K: CAMP4 Therapeutics Presents Positive Preclinical Data for CMP-002

CAMP4 Therapeutics announced new preclinical data showing CMP-002 significantly improves seizure phenotypes in a SYNGAP1-related disorder mouse model, advancing towards a Phase 1/2 trial.

Summary

• CAMP4 Therapeutics presented new preclinical data for its lead therapeutic candidate, CMP-002, at the TIDES Oligonucleotide & Peptide Therapeutics conference on May 14, 2026.
• The data demonstrate that CMP-002 administration resulted in statistically significant improvements in both seizure threshold and severity in a SYNGAP1 haploinsufficient mouse model.
• These results build upon prior evidence of neurodevelopmental benefits and suggest CMP-002 may address a broad range of symptoms associated with SYNGAP1-related disorder (SRD).
• The company plans to advance CMP-002 into a Phase 1/2 clinical trial in individuals with SRD in the second half of 2026.
• CMP-002 is an investigational antisense oligonucleotide (ASO) therapeutic designed to upregulate SYNGAP1 gene expression.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the statistically significant preclinical results and clear path towards clinical trials, although it remains early-stage.

Positives

• Statistically significant improvement in seizure threshold and severity in a SYNGAP1 haploinsufficient mouse model.
• Data suggest CMP-002 may address a broad range of SRD symptoms by restoring SYNGAP1 protein levels.
• Prior preclinical evidence of neurodevelopmental benefit is reinforced by new seizure data.
• Dose-dependent increases in SYNGAP protein expression demonstrated in patient-derived neurons.
• Reversal of disease-relevant behavioral phenotypes observed in a humanized haploinsufficient mouse model.
• Broad brain distribution with significant SYNGAP protein upregulation in non-human primates.
• Advancement to a Phase 1/2 clinical trial expected in the second half of 2026.

Negatives

• The study used a chemically induced seizure model (PTZ) as SYNGAP1 haploinsufficient mice do not exhibit spontaneous seizures.
• SYNGAP1-related disorder is characterized by a constellation of neurological symptoms, and seizure improvement is only one aspect.
• The company is still in the clinical-stage, with no approved disease-modifying therapies currently available for SRD.

Risks

• Uncertainty of preclinical and clinical development, which is lengthy, expensive, and characterized by uncertain outcomes.
• Risks related to additional costs or delays in completing development and commercialization.
• Dependence on senior management and clinical/scientific personnel, and the ability to retain them.
• Risks related to the complex manufacturing of product candidates and potential difficulties with third-party manufacturers.
• Ability to obtain and maintain sufficient intellectual property protection.
• Potential for unknown risks and uncertainties to emerge in an evolving environment.

Future Outlook

CAMP4 Therapeutics expects to advance CMP-002 into a Phase 1/2 clinical trial in individuals with SYNGAP1-related disorder in the second half of 2026. The company believes that by restoring SYNGAP1 protein towards healthy levels, CMP-002 may address a broad range of symptoms that define this disease.

Management Comments

• "SYNGAP1-related disorder is characterized by a constellation of neurological symptoms, of which seizures are among the most common, resulting in a devastating burden on patients and their families," said Daniel Tardiff, PhD, Chief Scientific Officer of CAMP4.
• "Our prior work established that CMP-002 can meaningfully restore motor and behavioral function in preclinical models, and these new seizure data are an important extension of that story."
• "Given this evidence, we believe that by restoring SYNGAP1 protein towards healthy levels, CMP-002 may address a broad range of symptoms that define this disease. We look forward to sharing these findings with the broader oligonucleotide therapeutics community at TIDES."

Industry Context

StockSavvy.ai notes that the presentation of positive preclinical data for CMP-002 in a rare genetic disorder like SYNGAP1-related disorder is a significant step for CAMP4 Therapeutics. The focus on regulatory RNA-targeting therapeutics to upregulate gene expression aligns with emerging trends in biopharmaceutical research aimed at addressing the root causes of genetic diseases.

Stakeholder Impact

• Shareholders may see increased interest due to positive preclinical data and progression towards clinical trials.
• Patients and families affected by SYNGAP1-related disorder have potential hope for a future disease-modifying therapy.
• The scientific and medical community will be informed of new developments in SRD treatment through the TIDES conference presentation.

Next Steps

• Advance CMP-002 into a Phase 1/2 clinical trial in individuals with SYNGAP1-related disorder in the second half of 2026.
• Present findings to the broader oligonucleotide therapeutics community at TIDES.

Key Dates

Recommendation

The filing presents positive preclinical data for CMP-002, a promising step towards a potential therapy for SYNGAP1-related disorder. However, the company is still in the clinical-stage, and significant risks remain in clinical development and regulatory approval. Therefore, a 'hold' recommendation is appropriate pending further clinical trial results.

Keywords

CAMP4 Therapeutics, CMP-002, SYNGAP1-related disorder, oligonucleotide therapeutics, antisense oligonucleotide, preclinical data, seizure disorder, gene expression